Expression profile of microRNAs in expressed prostatic secretion of healthy men and patients with IIIA chronic prostatitis/ chronic pelvic pain syndrome

// Ye Chen 1, * , SuNing Chen 2, * , Jian Zhang 3, * , YangMin Wang 4 , Zhengping Jia 5 , Xin Zhang 4 , Xiao Han 4 , Xiuquan Guo 4 , XiaoDi Sun 4 , Chen Shao 6 , Ji Wang 7 and Tian Lan 4, 6 1 Department of Anesthesiology and Pain, Lanzhou General Hospital of Lanzhou Command, Lanzhou, China 2 Department of Pharmacy, Xijing Hospital, The Fourth Military Medical University, Xi’an, China. 3 Department of Biochemistry and Molecular Biology and the State Key Laboratory of Cancer Biology, The Fourth Military Medical University, Xi'an, China 4 Department of Urology, Lanzhou General Hospital of Lanzhou Command, Lanzhou, China 5 Key Laboratory of the Plateau of the Environmental Damage Control, Lanzhou General Hospital of Lanzhou Military Command, Lanzhou, China 6 Department of Urology, Xiang’an Hospital, University of XiaMen, Xiamen, China 7 Laboratory of Cell Death and Cancer Genetics, The University of Minnesota Hormel Institute, Austin, MN, United States * These authors contributed equally to this work Correspondence to: Tian Lan, email: lantianuro@hotmail.com Ji Wang, email: jiwang924@gmail.com Keywords: prostate; microRNAs; chronic prostatitis/chronic pelvic pain syndrome; mir-21; high-throughput sequencing Received: August 23, 2017      Accepted: November 26, 2017      Published: January 06, 2018 ABSTRACT The current study aimed to identify a comprehensive expression-profile of microRNAs (miRNAs) in expressed prostatic secretion (EPS) collected from healthy men and patients with CP/CPPS (Chronic prostatitis/Chronic pelvic pain syndrome). After clinical screening of 382 participants, 60 healthy men and 59 IIIA CP/CPPS patients with significant pelvic-pain were included into this study from March 2012 to December 2014. High-throughput sequencing was employed to identify characteristic expression-profile of EPS-miRNAs. QRT-PCR was further performed to confirm elevated levels of differential EPS-miRNAs. Finally, candidate EPS-miRNAs were measured traceably in 21 follow-up patients and their classify-accuracy on IIIA CP/CPPS were analyzed by ROC (receiver operating characteristic) curve. In discovery-phage, 41 and 43 predominant EPS-miRNAs were found in pooled EPS-sample from 40 healthy men and 39 IIIA CP/CPPS patients, respectively. Furthermore, 22 abundant EPS-miRNAs were up-regulated with ≥ 2-fold in 20 patients compared to 20 healthy men. In testing-phage, elevated levels of miR-21-5p,miR-30a-5p, miR-30d-5p, miR-103a-3p and miR-141-3p were further confirmed in 33 patients by comparing to 30 healthy men. In validation-phage, relieved pelvic-pain symptom of 21 follow-up patients was found to be accompanied by significant down-regulation of miR-21-5p, miR-103a-3p and miR-141-3p. Particularly, ROC curve analysis indicated the highest area under ROC curve (AUC) was found for miR-21-5p (0.891), followed in order by miR-141-3p and miR-103a-3p. Our studies provided evidence that secretory miRNAs existed in EPS and dysregulated EPS-miRNAs were associated with prostatitis. In particular, miR-21-5p possessed a high classify-accuracy for IIIA CP/CPPS patients with significant pelvic pain.